APA (7th ed.) Citation

Popat, S., Januszewski, A., O'Brien, M., Ahmad, T., Lewanski, C., Dernedde, U., . . . Hackshaw, A. (2025). Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy: Clinical Studies. British Journal of Cancer, 132(3), 245. https://doi.org/10.1038/s41416-024-02901-6

Chicago Style (17th ed.) Citation

Popat, Sanjay, et al. "Long Term Efficacy of First-line Afatinib and the Clinical Utility of CtDNA Monitoring in Patients with Suspected or Confirmed EGFR Mutant Non-small Cell Lung Cancer Who Were Unsuitable for Chemotherapy: Clinical Studies." British Journal of Cancer 132, no. 3 (2025): 245. https://doi.org/10.1038/s41416-024-02901-6.

MLA (9th ed.) Citation

Popat, Sanjay, et al. "Long Term Efficacy of First-line Afatinib and the Clinical Utility of CtDNA Monitoring in Patients with Suspected or Confirmed EGFR Mutant Non-small Cell Lung Cancer Who Were Unsuitable for Chemotherapy: Clinical Studies." British Journal of Cancer, vol. 132, no. 3, 2025, p. 245, https://doi.org/10.1038/s41416-024-02901-6.